Abstract:Tankyrase (TNKS) enzymes remained central biotargets to treat Wnt-driven colorectal cancers. The success of Olaparib posited the druggability of PARP family enzymes depending on their role in tumor proliferation. In this work, an MD-simulation-based comparative assessment of the protein–ligand interactions using the best-docked poses of three selected compounds (two of the designed and previously synthesized molecules obtained through molecular docking and one reported TNKS inhibitor) was performed for a 500 ns period. The PDB:ID-7KKP and 3U9H were selected for TNKS1 and TNKS2, respectively. The Molecular Mechanics Generalized Born Surface Area (MM-GBSA) based binding energy data exhibited stronger binding of compound-15 (average values of −102.92 and −104.32 kcal/mol for TNKS1 and TNKS2, respectively) as compared to compound-22 (average values of −82.99 and −85.68 kcal/mol for TNKS1 and TNKS2, respectively) and the reported compound-32 (average values of −81.89 and −74.43 kcal/mol for TNKS1 and TNKS2, respectively). Compound-15 and compound-22 exhibited comparable or superior binding to both receptors forming stable complexes when compared to that of compound-32 upon examining their MD trajectories. The key contributors were hydrophobic stacking and optimum hydrogen bonding allowing these molecules to occupy the adenosine pocket by interfacing D-loop residues. The results of bond distance analysis, radius of gyration, root mean square deviation, root mean square fluctuation, snapshots at different time intervals, LUMO–HUMO energy differences, electrostatic potential calculations, and binding free energy suggested better binding efficiency for compound-15 to TNKS enzymes. The computed physicochemical and ADMET properties of compound-15 were encouraging and could be explored further for drug development. Communicated by Ramaswamy H. Sarma

Design, synthesis, and biological evaluation of isoquinolin-1(2 H)-one derivates as tankyrase-1/2 inhibitors

Design, synthesis and biological activity evaluation of novel inhibitors targeting TNKS2, based on docking, virtual screening and molecular dynamics simulation studies

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors

Substitutions at the C-8 position of quinazolin-4-ones improve the potency of nicotinamide site binding tankyrase inhibitors

Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors

New molecular insights for 4H-1,2,4-triazole derivatives as inhibitors of tankyrase and Wnt-signaling antagonist: a molecular dynamics simulation study

Identification of honokiol‐based scaffold to design tankyrase 1/2 inhibitors by in silico and in vitro studies

Discovery of Novel Tankyrase Inhibitors through Molecular Docking-Based Virtual Screening and Molecular Dynamics Simulation Studies

Design, Synthesis and Evaluate of Indazolylaminoquinazoline Derivatives As Potent Tropomyosin Receptor Kinase (TRK) Inhibitors

Design, Synthesis and Biological Evaluation of Thienopyridinones As Chk1 Inhibitors

Design, Synthesis and Structure–activity Relationship of Indolylindazoles As Potent and Selective Covalent Inhibitors of Interleukin-2 Inducible T-cell Kinase (ITK)

Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6 H-pyrimido[5,4- b][1,4]oxazin-7(8 H)-one Derivatives as A New Class of Potent Inhibitors of Pan-Trk and Their Drug-Resistant Mutants

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships

Design of New Second‐Generation TRK Inhibitors Targeting Tropomyosin Receptor Kinases by Using Molecular Docking, Molecular Dynamics Simulations and ADMET Properties

Identification and structural analysis of a selective tropomyosin receptor kinase C (TRKC) inhibitor

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Design, Synthesis and Biological Evaluation of C-Met Kinase Inhibitors Bearing 2-Oxo-1,2-dihydroquinoline Scaffold

Design and Synthesis of Novel Benzo[D]Oxazol-2(3h)-One Derivatives Bearing 7-Substituted-4-enthoxyquinoline Moieties As C-Met Kinase Inhibitors

Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors